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Objectives:  To compare serum testosterone and prostate specific antigen (PSA) levels of patients diagnosed
of prostate cancer to those with benign prostatic hyperplasia (BPH).
Subjects  and  methods:  One hundred and thirteen male patients with or without LUTS who had indica-
tion(s) for prostate biopsies were recruited. Blood samples were analysed for serum testosterone and serum
PSA. Prostate sizes were measured and PSA densities calculated before trans-rectal prostate biopsies were
performed.
Results: On histology of prostate biopsy specimens, 54 patients (47.8%) had prostate adenocarcinoma
while 59 patients (52.2%) had BPH. Serum testosterone levels were lower in the prostate cancer group
(23.09 ±  2.31 nmol/L versus  24.37 ±  1.94 nmol/L in the BPH group) but this difference was not statistically
significant (p  = 0.671). Serum testosterone also did not differ significantly with Gleason grade and Gleason
score in patients with prostate cancer.
Serum PSA and PSA density (PSAD) values were significantly higher in men with prostate cancer, and also
in prostate cancer patients with high grade disease.
Conclusion:  Serum testosterone levels of patients with prostate cancer did not significantly differ from
those of patients with BPH and were not related to grade in prostate cancer patients.
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rostate cancer is the second most frequently diagnosed cancer
f men and the incidence varies by race/ethnicity, with African-
mericans at highest risk in America [1]. In the African subregion,
rostate cancer presents approximately a decade earlier than it
oes in western countries, however, the patients still present with
dvanced disease in over 70% of cases [2,3]. In these patients, the
isease also tends to progress more rapidly and Gleason score tends
o be higher [3]. Though the Nigerian nationwide incidence is yet
o be directly evaluated [2], Nigerian men seem to be at also at high
isk of prostate cancer like the African-Americans judging from
ata gleaned from the population-based and hospital based can-
er registries which indicate that prostate cancer is the commonest
alignant tumour among Nigerian men [4].
hough the search for novel (and more prostate cancer specific)
umour markers continues, serum PSA estimation remains an impor-
ant tool for Prostate cancer detection [5]. Tissue and serum level
f androgens in those with or without prostate cancer have over the
ears been part of the focus of the search for better tumour markers
or prostate cancer. Serum testosterone and other androgens are con-
idered important in the growth and development of the prostate as
ell as in the pathogenesis of prostate cancer [6]. However, over the
ears, reports have been conflicting with no clear consensus and the
mportance of its determination for patient management in terms of
iagnosis, prognosis and staging has been poorly understood [6,7].
esearchers have at different times reported low serum testosterone
evels [8–10] and high serum testosterone levels [11,12] in patients
ith prostate cancer when compared to those without prostate can-
er. Some found no significant differences in serum testosterone
evels on comparison [13–16]. A review of 25 studies comparing
estosterone levels in a total of 2767 controls and 1481 patients with
rostate cancer reported that the mean testosterone levels at diag-
osis were the same in both groups in 15 studies (60%), higher in
rostate cancer patients in four (16%) and lower in six (24%) [6].
fter an online PUBMED search, a study conducted in our institu-
ion by Osegbe and Ogunlewe [17] (published in 1988) was the
nly similar study found. They measured and compared serum
estosterone levels in prostate cancer, benign prostatic hyperplasia
BPH) and normal patients and found that serum testosterone was
ignificantly lower in those with prostate cancer.
here is a paucity of studies of such research in the predominantly
lack sub-Saharan Africa, therefore, we also sought to compare
re-treatment serum testosterone levels in benign prostatic hyper-
lasia (BPH) and prostate cancer patients presenting in our centre
n Nigeria.
ubjects  and  methods
his study was a prospective comparative study conducted at our
nstitution over 16 months (March 2013–June 2014). Approval was
btained from the Research and Ethics Committee of the Lagos
niversity Teaching Hospital before commencement of the study.
ale patients above 40 years with or without symptoms of prostaticisease who had indications for prostate biopsy were enrolled into
he study from the Urology Outpatient Clinics and wards after
nformed consent had been obtained. The indications for prostate
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ectal examination and/or serum PSA elevated above the level
xpected for age. The age-specific levels used were 0–2.5 ng/ml
or men aged 40–49 years, 0–3.5 ng/ml for those aged 50–59 years,
–4.5 ng/ml for those aged 60–69 years and 0–6.5 ng/ml for those
ged 70–79 years. Patients excluded from the study were those on
-  reductase inhibitors, those that already had radiotherapy as treat-
ent before presentation, those already on androgen deprivation
herapy and men on androgen supplementation for hypogonadism.
ther clinical data collected included the bio-data (age, sex,
ccupation, marital status), presenting complaints, duration of
llness/problems, history presenting complaints including lower uri-
ary tract symptoms and haematuria, any history suggestive of
xpected complications (like acute urinary retention, renal fail-
re), history suggestive of prostatic malignancy (and metastases)
nd history of co-morbid conditions (e.g. diabetes mellitus, hepatic
iseases, hypertension). Physical examination findings were also
oted.
asting blood samples were collected between 7 am and 10 am.
erum was stored at −80 ◦C and were subsequently analysed by
uantitative determination for serum prostate specific antigen and
estosterone using enzyme immunoassay kits made by Rapid labs
UK). Analytical sensitivity for the total PSA assay kit was 0.3 ng/ml
hile that of the total testosterone kit was 0.2 nmol/l. The analysis
f the serum samples were done by 2 chemical pathologists working
ogether who were blinded to the histology results or clinical status
f the patients.
he sizes of the prostates were measured using a 3.5 MHz trans-
bdominal ultrasound probe and the volumes were expressed in
m3. Subsequently, trans-rectal prostate biopsies (minimum of 10
ores −  sextant + 4 extended cores) were done for all patients with
istology of the prostate biopsy specimens which formed the basis
or categorising the patients into 2 groups – prostate cancer group
nd benign prostatic hyperplasia (BPH) group. The Gleason grades
nd scores were also recorded for the prostate adenocarcinoma spec-
mens on histology. The histology of the specimens was done by a
athologist specialised in prostatic diseases who was blinded to the
esults of the serum PSA and testosterone.
he data were analysed using the Statistical Package of Social Sci-
nces (SPSS) version 16.0. The Student’s t-test was used for test of
ignificance with confidence interval of 95%. A p-value of <0.05
as considered statistically significant.
esults
 total of 113 patients were recruited and on histology of the prostate
iopsy specimens, 54 men (47.8%) had prostate cancer (prostate
ancer group) while 59 men (52.2%) had benign prostatic hyper-
lasia (BPH group). The overall mean age was 67.9 ±  7.8 years
range 47–85 years) while the mean ages were 68.9 ±  7.9 years and
6.9 ±  7.6 years in the prostate cancer and BPH groups respectively.
atients in their seventh and eighth decades of life cumulatively
ccounted for 75.1% of all patients.verall, the mean serum PSA was 30.23 ±  26.41 ng/ml (range
.02–88.36 ng/ml) while the overall mean serum testosterone was
3.8 ±  15.9 nmol/L (range 1.25–95.05 nmol/L). Within the individ-
al groups, 46 (75.93%) of patients in BPH group had serum PSA
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Table  1  Serum testosterone, PSA levels and PSA density in the 2 groups.
Variables Prostate cancer group (n = 54) BPH group (n = 59) p-Value
Age (years, mean ± SD) 68.9 ± 7.9 66.9 ± 7.6 0.170
Serum testosterone (nmol/L, mean ± SD) 23.1 ± 16.9 24.4 ± 14.9 0.671






































PSA density (ng/ml per ml, mean ± SD) 1.02 ± 2.4
levels <20 ng/ml while 41 (77.96%) of prostate cancer patients had
serum PSA levels ≥20 ng/ml.
Mean serum PSA levels were 45.8 ±  24.3 ng/ml and
16 ±  19.4 ng/ml in the prostate cancer group and BPH group
respectively with statistically significant difference on comparison
(p-value = <0.001) while the serum testosterone levels were
23.1 ±  16.9 nmol/L and 24.4 ±  14.9 nmol/L in the prostate cancer
and BPH groups respectively with no statistically significant
difference on comparison (p-value = 0.671) as shown in Table 1.
The PSA density showed statistically significant difference on
comparison with mean values being 1.02 ±  2.4 ng/ml/ml in the
prostate cancer group and 0.2 ±  0.2 ng/ml/ml in the BPH group.
On further analysis of the prostate cancer group, Gleason grade 4
was the primary grade in 23 (42.6%) of the patients in the group
while Gleason grade 3 was the primary pattern in 18 (33.3%). In
the group, 24 (44.4%) had Gleason scores of ≥8 while patients
with Gleason scores 6 and 7 cumulatively accounted for 24 (44.4%)
more of the patients. The mean serum testosterone levels were
20.2 ±  14.1 nmol/L and 27.3 ±  20.1 nmol/L in those with primary
Gleason’s grades ≥4 and those with primary Gleason’s grades <4
respectively with no statistically significant difference on compari-
son (Table 2).
Mean serum testosterone results levels of those with Gleason’s
scores <8 was 24.1 ±  18.1 nmol/L compared to 21.8 ±  15.7 nmol/L
in those with Gleason scores ≥8 as also shown in Table 2 (p-
value = 0.631). The serum PSA levels were significantly higher in
those with primary Gleason grade ≥4 and in those with Gleason
scores ≥8 as shown by the p-values of 0.017 and 0.027 respectively
(Table 2).
Discussion
Patients in their seventh and eighth decades of life cumulatively
accounted for 75.1% of the overall number studied and most patients
with prostate cancer had high risk disease as evidenced by percent-
age with serum PSA >20 ng/ml and Gleason grade ≥4 or Gleason
score ≥8. These findings are similar to previously published data
and confirm that prostatic diseases are significant problems of men
in our region and that the black Nigerian male usually presents with




Table  2  Serum testosterone and PSA levels of patients in different prima
Variables Primary Gleason grade 
≥4 (n = 32) <4 (n = 22) 
Serum testosterone (nmol/L, mean ± SD) 20.2 ± 14.1 27.3 ± 20.1
Serum PSA level (ng/ml, mean ± SD) 52.2 ± 21.4 36.4 ± 25.60.2 ± 0.2 0.016
rom the results of our study, the serum PSA (and calculated PSA
ensity) showed significant difference in values on comparison and
as higher in patients with prostate cancer when compared to those
ith BPH (p  = <0.001 for serum PSA and p  = 0.16 for PSA density).
n their study using suprapubic prostatectomy specimens, Hill et al.
16] also demonstrated that the serum PSA was the best discrimina-
or between those with and those without prostate cancer after they
ound that the serum PSA was significantly higher in those with
rostate cancer (p  < 0.00001, Mann–Whitney test).
n the prostate cancer group, the serum total PSA was also found
o be significantly higher in those with primary Gleason grades ≥4
nd Gleason scores ≥8 when compared to those with lower grades
r scores. Schatzl et al. [19] also found that patients with high grade
rostate cancer (Gleason score ≥8) had significantly higher serum
SA values.
n our study, the serum testosterone levels found to be slightly
ower in patients with prostate cancer but there was no statistically
ignificant difference from the serum levels in BPH patients (p-
alue = 0.671). Heracek et al. [7] also compared serum androgen
evels in patients with BPH and prostate cancer and found no sig-
ificant difference in levels. Samples used for histologic diagnosis
n the study by Heracek et al. [7] were simple and radical prosta-
ectomy specimens unlike the prostate biopsy specimens used in
ur study but the results were still similar. Other similar studies
omparing BPH and prostate cancer patients also demonstrated no
ignificant difference in serum testosterone [11,16,20]. Our find-
ngs however were different from that of Osegbe and Ogunlewe
17] (conducted in our institution and published in 1988) which
howed that in Nigerian patients with advanced prostatic cancer,
he serum testosterone concentrations were significantly lower than
hose of Nigerians with normal prostate and BPH. The patients with
rostate cancer in our study included both patients with advanced
and/or metastatic) disease and those with organ confined disease.
segbe and Ogunlewe [17] also studied androgen metabolites and
he androgen concentration in the prostatic glands of their patients.
ower serum testosterone levels in patients with prostate cancer
ere also reported by authors in other centres [8–10].here were no significant differences in the serum testosterone
alues when those with primary Gleason grades ≥4 and Gleason
cores ≥8 were compared to those with lower grades or scores,
ry Gleason grade and Gleason score categories.
Gleason score
p-Value ≥8 (n = 24) <8 (n = 30) p-Value
 0.135 21.8 ± 15.7 24.1 ± 18.1 0.631


















































espectively. Similar findings were demonstrated by Massengill
t al. [21] in their study though the specimens used for histology
ere radical prostatectomy specimens. This is a major limitation
n our study since grading between prostate biopsy specimens and
he more representative radical prostatectomy specimen may be
iscordant due to sampling errors with the needle biopsy and higher
rade adenocarcinoma may be missed [22]. Also, adenocarcinoma
ay be entirely missed on needle biopsy due to same sampling
rror [23]. However, grade on biopsy material has also been shown
o correlate fairly well with that of the subsequent prostatectomy
pecimen especially with extended biopsy protocols rather than sex-
ant biopsy protocol [22,23]. On the other hand, studies by Schatzl
t al. [19] and Ide et al. [20] found that patients with high grade
rostate cancer had significantly lower serum testosterone values.
onclusion
erum testosterone levels in prostate cancer patients (though lower)
ere not significantly different statistically from the levels in BPH
atients. Serum testosterone levels did not also significantly differ
ith pathological grade in prostate cancer patients.
rostate specific antigen (PSA) and PSA density on the other hand
ere significantly higher in the prostate cancer group of patients.
he serum PSA level was also higher in those with high grade
rostate cancer when compared to those with lower grades. Thus,
erum PSA (with or without DRE) assay currently still remains an
mportant investigation for detecting prostate cancer in men.
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onflict  of  interest
one declared.
ource  of  funding
he research project was funded by the authors with no external
ource of funds or grant.
eferences
[1] Leitzmann MF, Rohrmann S. Risk factors for the onset of pros-
tatic cancer: age, location, and behavioral correlates. Clin Epidemiol
2012;4:1–11.
[2] Ifere GO, Abebe F, Ananaba GA. Emergent trends in the reported
incidence of prostate cancer in Nigeria. Clin Epidemiol 2012;4:19–32.
[3] Bowa K. An overview of the diagnosis and management of prostate
cancer in Nigeria: experience from a north-central state of Nigeria.
Ann Afr Med 2010;9(3):111–2.
[4] Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowale T, Igbinoba
F, et al. Cancer incidence in Nigeria: a report from population-based
cancer registries. Cancer Epidemiol 2012;36(5):e271–8.
[
D.E. Orakwe et al.
[5] Obort AS, Ajadi MB, Akinloye O. Prostate-specific antig: any successor
in sight? Rev Urol 2013;15(3):97–107.
[6] Slater S, Oliver RT. Testosterone: its role in development of prostate
cancer and potential risk from use as hormone replacement therapy.
Drugs Aging 2000;17(6):431–9.
[7] Heracek J, Hampl R, Hill M, Starka L, Sachova J, Kuncova J, et al.
Tissue and serum levels of principal androgens in benign prostatic
hyperplasia and prostate cancer. Steroids 2007;72(4):375–80.
[8] Sofikerim M, Eskicorapci S, Oruc O, Ozen H. Hormonal predictors of
prostate cancer. Urol Int 2007;79(1):13–8.
[9] Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, et al.
Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Urol Int 2008;80(2):134–40.
10] Morgentaler A, Bruning 3rd CO, DeWolf WC. Occult prostate can-
cer in men with low serum testosterone levels. JAMA 1996;276(23):
1904–6.
11] Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya
A, et al. The clinical potential of pretreatment serum testosterone
level to improve the efficiency of prostate cancer screening. Eur Urol
2007;51(2):375–80.
12] Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG. A pilot study
analyzing PSA, serum testosterone, lipid profile, body mass index and
race in a small sample of patients with and without carcinoma of the
prostate. Prostate Cancer Prostatic Dis 2001;4(2):101–5.
13] Hsing AW, Comstock GW. Serological precursors of cancer: serum
hormones and risk of subsequent prostate cancer. Cancer Epidemiol
Biomark Prev 1993;2:27–32.
14] Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones
and prostate cancer: a collaborative analysis of 18 prospective studies.
J Natl Cancer Inst 2008;100(3):170–83.
15] de Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW,
van der Maas PJ, et al. Peripheral hormone levels in controls and
patients with prostatic cancer or benign prostatic hyperplasia: results
from the Dutch–Japanese case–control study. Cancer Res 1991;51:
3445–50.
16] Hill M, Bilek R, Safarik L, Starka L. Analysis of relations between
serum levels of epitestosterone, estradiol, testosterone, IGF-1 and
prostatic specific antigen in men with benign prostatic hyperplasia
and carcinoma of the prostate. Physiol Res Acad Sci Bohemoslov
2000;49(Suppl. 1):S113–8.
17] Osegbe DN, Ogunlewe JO. Androgen concentration in blacks with
benign and malignant prostatic disease. J Urol 1988;140:160–4.
18] Ajape AA, Ibrahim KO, Fakeye JA, Abiola OO. An overview of cancer
of the prostate diagnosis and management in Nigeria: the experience in
a Nigerian tertiary hospital. Ann Afr Med 2010;9(3):113–7.
19] Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Hai-
tel A, et al. High-grade prostate cancer is associated with low serum
testosterone levels. Prostate 2001;47(1):52–8.
20] Ide H, Yasuda M, Nishio K, Saito K, Isotani S, Kamiyama Y, et al.
Development of a nomogram for predicting high-grade prostate cancer
on biopsy: the significance of serum testosterone levels. Anticancer Res
2008;28(4C):2487–92.
21] Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C,
et al. Pretreatment total testosterone level predicts pathological stage in
patients with localized prostate cancer treated with radical prostatec-
tomy. J Urol 2003;169(5):1670–5.
22] Epstein JI. Pathology of prostatic neoplasia. In: Wein AJ, Kavoussi LR,
Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology.
10th ed. Philadelphia, PA: Elsevier Saunders; 2012. p. 2726–34.
23] Presti JC. Prostate biopsy: current status and limitations. Rev Urol
2007;9(3):93–8.
